riluzole has been researched along with MS (Multiple Sclerosis) in 12 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease." | 4.80 | [New therapies in neurology, but who benefits?]. ( de Haan, RJ; Vermeulen, M, 1999) |
| "Riluzole is a neuroprotective agent that inhibits the release of glutamate from nerve terminals and modulates glutamate, i." | 2.71 | Glutamate inhibition in MS: the neuroprotective properties of riluzole. ( Kalkers, NF; Killestein, J; Polman, CH, 2005) |
| "Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients." | 1.43 | Longitudinal associations between brain structural changes and fatigue in early MS. ( Azevedo, C; Maghzi, AH; Nourbakhsh, B; Nunan-Saah, J; Pelletier, D; Spain, R; Waubant, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Foley, P | 1 |
| Parker, RA | 2 |
| de Angelis, F | 2 |
| Connick, P | 2 |
| Chandran, S | 2 |
| Young, C | 1 |
| Weir, CJ | 2 |
| Chataway, J | 2 |
| Plantone, D | 1 |
| Doshi, A | 1 |
| John, N | 1 |
| Stutters, J | 1 |
| MacManus, D | 1 |
| Prados Carrasco, F | 1 |
| Barkhof, F | 1 |
| Ourselin, S | 1 |
| Braisher, M | 1 |
| Ross, M | 1 |
| Cranswick, G | 1 |
| Pavitt, SH | 1 |
| Giovannoni, G | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Hawkins, C | 1 |
| Sharrack, B | 1 |
| Bastow, R | 1 |
| Stallard, N | 1 |
| Hollingworth, S | 1 |
| Walker, K | 1 |
| Page, A | 1 |
| Eadie, M | 1 |
| Maghzi, AH | 3 |
| Revirajan, N | 2 |
| Julian, LJ | 2 |
| Spain, R | 3 |
| Mowry, EM | 1 |
| Liu, S | 1 |
| Jin, C | 2 |
| Green, AJ | 1 |
| McCulloch, CE | 1 |
| Pelletier, D | 3 |
| Waubant, E | 5 |
| Nourbakhsh, B | 4 |
| Azevedo, C | 1 |
| Nunan-Saah, J | 2 |
| Lazar, A | 1 |
| Julian, L | 1 |
| Gilgun-Sherki, Y | 1 |
| Panet, H | 1 |
| Melamed, E | 1 |
| Offen, D | 1 |
| Killestein, J | 1 |
| Kalkers, NF | 1 |
| Polman, CH | 1 |
| Palace, J | 1 |
| Vermeulen, M | 1 |
| de Haan, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial[NCT04979546] | 356 participants (Anticipated) | Interventional | 2021-11-04 | Recruiting | |||
| MS Wellness Navigator: The Effect of Nurse Practitioner (NP-led) Care on Mood, Anxiety and Health Related Quality of Life in People With Multiple Sclerosis - A Randomized Trial[NCT04388592] | 248 participants (Actual) | Interventional | 2017-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for riluzole and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Neuroprotection and repair.
Topics: Adrenal Cortex Hormones; Animals; Humans; Multiple Sclerosis; Neuroprotective Agents; Riluzole; Woun | 2008 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-b | 1999 |
6 trials available for riluzole and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, C | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Brain; Cross-Sectional Studies; Disability Evaluation; Double-Blind M | 2014 |
Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis.
Topics: Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Fatigue; Female; Humans; Male; Middle | 2015 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Topics: Adult; Aged; Female; Follow-Up Studies; Glutamic Acid; Humans; Magnetic Resonance Imaging; Male; Mid | 2005 |
4 other studies available for riluzole and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geograph | 2013 |
Longitudinal associations between brain structural changes and fatigue in early MS.
Topics: Adult; Atrophy; Brain; Fatigue; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Ma | 2016 |
Longitudinal associations between MRI and cognitive changes in very early MS.
Topics: Adult; Cognition Disorders; Disease Progression; Female; Humans; Longitudinal Studies; Magnetic Reso | 2016 |
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Ex | 2003 |